TY - JOUR T1 - Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy JF - In Vivo JO - In Vivo SP - 1041 LP - 1049 DO - 10.21873/invivo.12348 VL - 35 IS - 2 AU - YORIKO HASEGAWA AU - NOBUAKI MATSUBARA AU - TAKAHIRO KOGAWA AU - YOICHI NAITO AU - KENICHI HARANO AU - AKO HOSONO AU - TATSUYA ONISHI AU - TAKASHI HOJO AU - MOTOTSUGU SHIMOKAWA AU - TORU MUKOHARA Y1 - 2021/03/01 UR - http://iv.iiarjournals.org/content/35/2/1041.abstract N2 - Aim: Patients with triple-negative breast cancer (TNBC) who have not achieved pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) were considered for adjuvant capecitabine. This study was to explore the utility of the Neo-Bioscore in guiding post-surgical therapy in TNBC. Patients and Methods: The Neo-Bioscore was calculated for patients with non-metastatic primary breast cancer who received NAC at National Cancer Center Hospital East, Japan. Results: A total of 329 patients were evaluated. The Neo-Bioscore stratified prognosis after NAC better than clinical or pathological stage. The Neo-Bioscore performed well in the selection of patients with TNBC with excellent prognoses despite non-pCR; no death was observed in patients who had a Neo-Bioscore of 2, the lowest score in those with TNBC. Conclusion: The Neo-Bioscore can improve the prognostic stratification of patients after NAC for breast cancer over clinical and pathological staging and may enable the identification of patients with non-pCR TNBC who can avoid additional adjuvant chemotherapy. ER -